• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Plasma IL-17A is increased in patients with critical MIS-C and associated to in-hospital mortality

tetano

Editor, Senior Moderator
Front Immunol


. 2025 Jan 27:15:1485009.
doi: 10.3389/fimmu.2024.1485009. eCollection 2024. Plasma IL-17A is increased in patients with critical MIS-C and associated to in-hospital mortality

Emmerson C F de Farias[SUP] 1 [/SUP], Luciana M P P do Nascimento[SUP] 1 [/SUP], Manoel J C Pavão Junior[SUP] 1 [/SUP], Dalila C A Pavão[SUP] 1 [/SUP], Ana P S Pinheiro[SUP] 1 [/SUP], Andreza H O Pinheiro[SUP] 1 [/SUP], Marília C B Alves[SUP] 1 [/SUP], Kíssila M M M Ferraro[SUP] 1 [/SUP], Larisse F Q Aires[SUP] 1 [/SUP], Luana G Dias[SUP] 1 [/SUP], Mayara M M Machado[SUP] 1 [/SUP], Michaelle J D Serrão[SUP] 1 [/SUP], Raphaella R Gomes[SUP] 1 [/SUP], Sara M P de Moraes[SUP] 1 [/SUP], Gabriela C L Pontes[SUP] 1 [/SUP], Railana D F P Carvalho[SUP] 1 [/SUP], Cristiane T C Silva[SUP] 1 [/SUP], Carla M A das Neves[SUP] 1 [/SUP], Joyce C L Dos Santos[SUP] 1 [/SUP], Adriana M B de Sousa[SUP] 1 [/SUP], Leda L da Silva[SUP] 1 [/SUP], Mary L F M F de Mello[SUP] 1 [/SUP], Patricia B Carvalho[SUP] 2 [/SUP], Renata de B Braga[SUP] 2 [/SUP], Kathia de O Harada[SUP] 2 [/SUP], Maria C A Justino[SUP] 3 [/SUP], Iran B Costa[SUP] 4 [/SUP], Igor Brasil-Costa[SUP] #[/SUP][SUP] 4 [/SUP], Marta C Monteiro[SUP] #[/SUP][SUP] 5 [/SUP], Gleice Clemente[SUP] #[/SUP][SUP] 6 [/SUP], Maria Teresa Terreri[SUP] #[/SUP][SUP] 6 [/SUP]



Affiliations
Abstract

Background: Multisystem inflammatory syndrome in children (MIS-C) is a rare and severe post-COVID-19 complication with multiple phenotypes.
Objectives: The aim of this study is to study inflammatory biomarkers (cytokines and oxidative stress) in critical MIS-C patients and to observe if there is association between these biomarkers and mortality.
Methods: A single-center prospective study enrolled patients with MIS-C (with positive molecular test), aged between 1 month and 18 years of age. Data was collected from 20 pediatric intensive care unit (PICU)'s bed. Inflammatory biomarkers (cytokines and oxidative stress markers) were performed on day 1 and 3 after hospitalization. Survival rate was calculated, and Kaplan-Meier curves were plotted. Univariate and multivariate Cox regression analyses were conducted. The ROC (Receiver Operating Characteristic) curve analysis was performed.
Results and conclusions: A total of 41 patients out of 109 patients admitted at PICU with suspected MIS-C during the study period were included, of which 33 (80.5%) were male, 9 (22%) were under one year old, and 30 (73.2%) presented comorbidities. Among them, 16 (39%) did not survive. The mean survival time was shorter in patients with higher levels of IL-17A (≥ 19.71 pg/mL) on day 1 (115 vs 323 days, p = 0.004). Higher levels of IL-17A on day 1 were associated with mortality in both the crude model (HR 1.03, CI95% 1.004-1.057, p = 0.022) and the adjusted model (HR 1.043, CI95% 1.013-1.075, p = 0.012). ROC analysis revealed a cut-off value for the IL-17A of 14.32 pg/ml. The other immunological and inflammatory markers did not demonstrate an association with survival (p>0.05). Our findings suggest that patients with high levels of IL-17A are at greater risk for death.

Keywords: COVID-19; cytokines; mortality; oxidative stress; pediatric intensive care unit; post-acute COVID-19 syndrome.

 
Back
Top Bottom